Navigation Links
BioMS Medical announces conference call and web cast for Annual General Meeting
Date:5/5/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, May 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), will hold its Annual General Meeting on Friday, May 9, 2008, at 2:00 p.m. (MT), 4:00 p.m. (ET).

A live audio webcast of the conference call will be available at http://www.biomsmedical.com. Please connect at least ten minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast.

Members of the professional investment community are invited to participate in the conference call by telephone.

DATE: Friday, May 9, 2008

TIME: 2:00p.m. (Mountain Time), 4:00 p.m. (Eastern Time)

DIAL IN NUMBER: 416 644-3430 or 1 800-814-4857

TAPED REPLAY: 1 877-289-8525 or 416 640-1917; available from

May 9, 2008 until May 16, 2008 at midnight

REFERENCE NUMBER: 21271314

About BioMS Medical Corp.

------------------------- BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Dr. Robert Hanzlik, whose ... toxicity carries implications for advancing the creation of safer ... National University , the second-largest private, nonprofit university ... Hanzlik, a professor at the University of Kansas School ... design, starts at 5 p.m. and takes place at ...
(Date:4/27/2015)... April 27, 2015 ... please scroll to bottom . Investor-Edge ... Pharmaceuticals Inc. (NASDAQ: LXRX ), Idera Pharmaceuticals ... (NASDAQ: SNTA ), Spectrum Pharmaceuticals Inc. (NASDAQ: ... MDVN ). Free research report on Lexicon Pharma ...
(Date:4/27/2015)... and HEIDELBERG , Germany ... Addresses unmet need in treatment of millions of ... has been granted a patent in Europe ... patent supports Molecular Health,s discovery that EPHB4 is a novel ... promotes tumor growth. EPO stimulates the production of red blood ...
(Date:4/27/2015)... 2015 Diasome Pharmaceuticals, Inc. (“Diasome”) ... Joslin Diabetes Center (“Joslin”) to collaborate on the ... novel Hepatocyte Directed Vesicle (“HDV”) targeting system for ... , Located in Boston, Massachusetts, Joslin is the ... organization dedicated to the prevention, treatment and cure ...
Breaking Biology Technology:Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2
... Imago Scientific Instruments has sold one of ... of Engineering for use in the new W.M. ... lab will be the primary research center of ISU's ... Narasimhan, an associate professor of chemical and biological engineering. ...
... has secured $5 million in a funding round led ... LLC. , ,The funding will allow Jellyfish to ramp up ... conjunction with the funding, retail industry veteran Ralph Dillon, managing ... of Directors. , ,Jellyfish has gained traction in online retailing ...
... research team at the Medical College of Wisconsin ... National Heart, Lung, and Blood Institute to support ... which was awarded to an investigative team led by pediatric ... molecular and clinical understanding of Von Willebrand disease ...
Cached Biology Technology:Online retailer Jellyfish.com lands $5M in funding 2Online retailer Jellyfish.com lands $5M in funding 3Medical College secures $9.7M research grant 2
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... the American Society of Tropical Medicine and Hygiene (ASTMH) -- ... bring together in one place global experts who are battling ... that each year kill or sicken hundreds of millions of ... medicine and global health will present new insights and research ...
... N.C. -- Recognizing that some of the leading ... are located in the Research Triangle Park area, ... $13.6 million grant to establish a multi-university center ... scientific endeavor. Researchers from Duke University, North ...
... Bethesda, MDA new commentary published online in The FASEB ... diligent and demand proof of safety and benefit before ... treatments have very little scientific evidence that they actually ... the article, Phillip J. Baker, Ph.D., Executive Director of ...
Cached Biology News:Latest on malaria, dengue, radiation threats, bedbugs, cholera in Haiti at ASTMH Annual Meeting 2Latest on malaria, dengue, radiation threats, bedbugs, cholera in Haiti at ASTMH Annual Meeting 3NSF establishes Triangle (NC) Center for Soft Matter Research 2NSF establishes Triangle (NC) Center for Soft Matter Research 3Chronic pain: Watch out before accepting diagnosis and treatment 2